Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD)

    Journal of the American Society of Nephrology Date published:

  • The impact of the COVID -19 pandemic on medical education

    Medical Journal of Australia Date published:

  • Effects of canagliflozin on serum potassium in the CANagliflozin cardioVascular Assessment Study (CANVAS) Program

    Clinical Kidney Journal Date published:

  • Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program

    Diabetes, Obesity and Metabolism Date published:

  • Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program

    Journal of the American Society of Nephrology Date published:

  • The impact of the COVID -19 pandemic on medical education

    Medical Journal of Australia Date published:

  • Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis

    Clinical Journal of the American Society of Nephrology Date published:

  • No evidence of a legacy effect on survival following randomization to extended hours dialysis in the ACTIVE Dialysis trial

    Nephrology Date published:

  • Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop

    American Journal of Kidney Diseases Date published:

  • Effects of Allopurinol on the Progression of Chronic Kidney Disease

    New England Journal of Medicine Date published:

  • The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial

    Diabetes, Obesity and Metabolism Date published:

  • Predictors of Change in Left-Ventricular Structure and Function in a Trial of Extended Hours Hemodialysis

    Journal of Cardiac Failure Date published:

  • 139-LB: The Redox Balance Predicts Both Cardiovascular (CV) and Renal Outcomes in CANVAS

    Diabetes Date published:

  • 27-OR: Effect of Canagliflozin on Total Hospitalization for Heart Failure Events in Patients with Type 2 Diabetes and Chronic Kidney Disease

    Diabetes Date published:

  • 1130-P: Mediators of the Effects of Canagliflozin (CANA) on Heart Failure (HF) and CV Death in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease (CKD)

    Diabetes Date published:

  • P1028EFFECTS OF CANAGLIFLOZIN ON MAJOR ADVERSE CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIFFERENT BASELINE LEVELS OF TYPE 2 DIABETES MELLITUS DISEASE SEVERITY: RESULTS FROM THE CANVAS PROGRAM

    Nephrology Dialysis Transplantation Date published: